Everolimus 5 mg vs 10 mg/Daily for Patients With Neuroendocrine Tumors

Clinical trial NCT06472388 · RECRUITING

Trial details

NCT number: NCT06472388
Sponsor: AC Camargo Cancer Center
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Neuroendocrine Tumors Progression Neuroendocrine Tumor Grade 1 Neuroendocrine Tumor Grade 2 Neuroendocrine Tumor of Pancreas Neuroendocrine Tumor of the Lung Neuroendocrine Tumor Carcinoid

Start date: 2024-04-24
Primary completion: 2026-05-20
Enrollment: 100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.